RE:The Most Important Detail in Today's NR...Just an addition to my post, I believe CGC will actually develop an entirely new medical brand which we'll eventually even see here in Canada to differentiate between rec and med. We can't really use Bedrocan as a medical brand internationally, and it wouldn't function well in the Americas. There is a growing consensus that there is a need and a massive potential market for targeted application of cannabinoids where opioids have been used previously. We've all speculated about what will happend if/when big pharma moves into this space, but in my opinion what we are seeing is the formation of the world's first cannabis derived pharma company. I believe CGC is and will lead the way in the research and development of directed medicinal cannabanoid therapy. AKA, CGC is becoming big pharma.
SquishyInc wrote: ...i think is in this excerpt...
"This acquisition establishes a distinct and purely medicinal corporate entity that helps us today but also positions us for domestic medicinal production inside Germany if the regulatory environment shifts."
I was wondering how Tweed would function internationally in the purely medical market when they are branded and geared to rec. This clears that up somewhat, and i suspect is CGC beginning to form a distinct medicinal arm, which will allow them to operate as such in Europe and elsewhere. The other implication, actually building a facility in Germany, is actually less important imo, but still exciting.
As an aside, i'm just jumping through the final hoops to become a gov sanctioned consumer of MMJ, and i've chosen Tweed as my supplier :D Here's to Future Growth!!!